Truist lowered the firm’s price target on Evolent Health (EVH) to $15 from $20 and keeps a Buy rating on the shares. The firm is updating its model after the company’s investor healthcare conference last week, noting that given the elevated level of utilization that Evolent experienced in November and lack of clarity into December trends, it is reducing its Q4 EBITDA estimates from $30M to $24M, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health price target lowered to $20 from $29 at BTIG
- Evolent Health price target lowered to $12 from $16 at Stephens
- Evolent Health price target lowered to $14 from $27 at UBS
- Evolent Health reiterates long-term outlook, says FY25 guide coming February 20
- Evolent dips after Truist warns guidance may be ‘significantly’ below consensus